PDCD1 and hepatocellular carcinoma: Nivolumab, a completely human anti-PD-1 antibody that binds to PD-1 on T cells to inhibit the interaction with PD-L1 and PD-L2, was tested in a phase I/II study in patients with HCC to determine its safety and preliminary anticancer efficacy [92].